7.28
7.28 (0%)
As of Feb 14, 2025
Ocular Therapeutix, Inc [OCUL]
Source:
Company Overview
Ocular Therapeutix, Inc is a biopharmaceutical company committed to redefining the retina experience. AXPAXLI (axitinib intravitreal hydrogel, also known as OTX-TKI), our product candidate for retinal disease, is based on our proprietary ELUTYX bioresorbable hydrogel-based formulation technology.
| Country | United States |
| Headquarters | bedford, massachusetts |
| Phone Number | (781) 357-4000 |
| Industry | manufacturing |
| CEO | Antony Mattessich |
| Website | www.ocutx.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $63.7 |
| Operating Profit | $-171.8 |
| Net Income | $-193.5 |
| Net Cash | $196.1 |
Profit Ratios
| Gross Margin | $58.1 |
| Operating Margin | -269.6 |
| Profit as % of Revenues | -30% |
| Profit as % of Assets | -54.5% |
| Profit as % of Stockholder Equity | -61.4% |
Management Effectiveness
| Return on Equity | -61.4% |
| Return on Assets | -42.3% |
| Turnover Ratio | 18% |
| EBITA | $-171.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $457.9 |
| Total Liabilities | $142.6 |
| Operating Cash Flow | $-134.7 |
| Investing Cash Flow | $-1.3 |
| Financing Cash Flow | $332.1 |
